Screening of differential microRNA expression in gastric signet ring cell carcinoma and gastric adenocarcinoma and target gene prediction

Oncology Reports

Volumn 33, Issue 6, 2015, Pages 2963-2971

  Chen, Jian ^a   Sun, Di ^a   Chu, Hongjin ^a   Gong, Zhaohua ^a   Zhang, Chenglin ^a   Gong, Benjiao ^a   Li, Yan ^a   Li, Ning ^a   Jiang, Lixin ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

Gastric adenocarcinoma; Gastric signet ring cell carcinoma; microRNA

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 665; MICRORNA 95; TRANSCRIPTION FACTOR GLI2; UNCLASSIFIED DRUG; GLI2 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; MIRN665 MICRORNA, HUMAN; MIRN95 MICRORNA, HUMAN; NUCLEAR PROTEIN; PHOSPHOLIPASE C GAMMA; PLCG1 PROTEIN, HUMAN;

ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; GASTRIC SIGNET RING CELL CARCINOMA; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GLI2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; PLCG1 GENE; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA EXTRACTION; SIGNET RING CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; UPREGULATION; ADENOCARCINOMA; BIOSYNTHESIS; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; CARCINOMA, SIGNET RING CELL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICRORNAS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOLIPASE C GAMMA; STOMACH NEOPLASMS;

EID: 84928902126     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3935     Document Type: Article

References (67)

1. Piazuelo MB and Correa P: Gastric cáncer: Overview. Colomb Med 44: 192-201, 2013.
2. Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64: 31-49, 1965.
3. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
4. Kim BS, Oh ST, Yook JH and Kim BS: Signet ring cell type and other histologic types: Differing clinical course and prognosis in T1 gastric cancer. Surgery 155: 1030-1035, 2014.
5. Kwon KJ, Shim KN, Song EM, Choi JY, Kim SE, Jung HK and Jung SA: Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. Gastric Cancer 17: 43-53, 2014.
6. Tabouret T, Dhooge M, Rouquette A, Brezault C, Beuvon F, Chaussade S and Coriat R: Gastric signet ring cell adenocarcinoma: A distinct entity. Presse Med 43: 353-357, 2014 (In French).
7. Huh CW, Jung H, Kim JH, Lee YC, Kim H, Kim H, Yoon SO, Youn YH, Park H, Lee SI, et al: Signet ring cell mixed histology may show more aggressive behavior than other histologies in early gastric cancer. J Surg Oncol 107: 124-129, 2013.
8. Hass HG, Smith U, Jäger C, Schäffer M, Wellhäuber U, Hehr T, Markmann HU, Nehls O and Denzlinger C: Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren's): Single-center experience of 160 cases. Onkologie 34: 682-686, 2011.
9. Llauradó M, Majem B, Altadill T, Lanau L, Castellví J, Sánchez-Iglesias JL, Cabrera S, De la Torre J, Díaz-Feijoo B, Pérez-Benavente A, et al: MicroRNAs as prognostic markers in ovarian cancer. Mol Cell Endocrinol 390: 73-84, 2014.
10. Mulrane L, Klinger R, McGee SF, Gallagher WM and O'Connor DP: microRNAs: A new class of breast cancer biomarkers. Expert Rev Mol Diagn 14: 347-363, 2014.
11. Xue Y, Abou Tayoun AN, Abo KM, Pipas JM, Gordon SR, Gardner TB, Barth RJ Jr, Suriawinata AA and Tsongalis GJ: MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm. Cancer Genet 206: 217-221, 2013.
12. Valencia-Sanchez MA, Liu J, Hannon GJ and Parker R: Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20: 515-524, 2006.
13. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R and Rajewsky N: Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63, 2008.
14. Li H, Meng F, Ma J, Yu Y, Hua X, Qin J and Li Y: Insulin receptor substrate-1 and Golgi phosphoprotein 3 are downstream targets of miR-126 in esophageal squamous cell carcinoma. Oncol Rep 32: 1225-1233, 2014.
15. Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M, Watari H, Mitamura T, Hosaka M, Hanley SJ, et al: MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget 5: 6049-6062, 2014.
16. Zhong D, Huang G, Zhang Y, Zeng Y, Xu Z, Zhao Y, He X and He F: MicroRNA-1 and microRNA-206 suppress LXRα-induced lipogenesis in hepatocytes. Cell Signal 25: 1429-1437, 2013.
17. Nygren MK, Tekle C, Ingebrigtsen VA, Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T, Alsner J, et al: Identifying microRNAs regulating B7-H3 in breast cancer: The clinical impact of microRNA-29c. Br J Cancer 110: 2072-2080, 2014.
18. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, et al: MicroRNA 29b functions in acute myeloid leukemia. Blood 114: 5331-5341, 2009.
19. Shenouda SK and Alahari SK: MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev 28: 369-378, 2009.
20. Ishiguro H, Kimura M and Takeyama H: Role of microRNAs in gastric cancer. World J Gastroenterol 20: 5694-5699, 2014.
21. Wang M, Zhao C, Shi H, Zhang B, Zhang L, Zhang X, Wang S, Wu X, Yang T, Huang F, et al: Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: Novel biomarkers and a mechanism for gastric cancer. Br J Cancer 110: 1199-1210, 2014.
22. Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, Kundel Y, Brenner R, Morgenstern S, Halpern M, et al: MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 17: 3976-3985, 2011.
23. Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW, Choi SH, Lee JS and Cho JY: Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype. World J Gastroenterol 19: 7078-7088, 2013.
24. Peng Y, Liu YM, Li LC, Wang LL and Wu XL: microRNA-503 inhibits gastric cancer cell growth and epithelial-to-mesenchymal transition. Oncol Lett 7: 1233-1238, 2014.
25. Shen ZY, Zhang ZZ, Liu H, Zhao EH and Cao H: miR-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expression. Exp Ther Med 7: 1757-1761, 2014.
26. Ren J, Huang HJ, Gong Y, Yue S, Tang LM and Cheng SY: MicroRNA-206 suppresses gastric cancer cell growth and metastasis. Cell Biosci 4: 26, 2014.
27. Peng Y, Guo JJ, Liu YM and Wu XL: MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Biosci Rep 34: 34, 2014.
28. Tsai MM, Wang CS, Tsai CY, Chen CY, Chi HC, Tseng YH, Chung PJ, Lin YH, Chung IH, Chen CY, et al: MicroRNA-196a/-196b promote cell metastasis via negative regulation of radixin in human gastric cancer. Cancer Lett 351: 222-231, 2014.
29. Wang T, Ge G, Ding Y, Zhou X, Huang Z, Zhu W, Shu Y and Liu P: MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J 127: 2357-2362, 2014.
30. Yang M, Shan X, Zhou X, Qiu T, Zhu W, Ding Y, Shu Y and Liu P: miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem 14: 884-891, 2014.
31. Aizawa K, Muto I, Suzuki S, Tanaka N, Yabusaki H, Tanaka S, Katayanagi N, Suzuki T, Tanaka O and Muto T: Augmentation of 5-fluorouracil cytotoxicity by epidermal growth factor in a newly established human signet-ring cell carcinoma of the stomach in culture. Surg Today 24: 420-428, 1994.
32. Shimada S, Mimata A, Sekine M, Mogushi K, Akiyama Y, Fukamachi H, Jonkers J, Tanaka H, Eishi Y and Yuasa Y: Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut 61: 344-353, 2012.
33. Takeuchi T, Adachi Y and Nagayama T: A WWOX-binding molecule, transmembrane protein 207, is related to the invasiveness of gastric signet-ring cell carcinoma. Carcinogenesis 33: 548-554, 2012.
34. Humar B, Blair V, Charlton A, More H, Martin I and Guilford P: E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res 69: 2050-2056, 2009.
35. Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW, Choi SH and Cho JY: Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol 18: 4037-4043, 2012.
36. Piessen G, Messager M, Le Malicot K, Robb WB, Di Fiore F, Guilbert M, Moreau M, Christophe V, Adenis A and Mariette C: Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002. BMC Cancer 13: 281, 2013.
37. Chen XP, Chen YG, Lan JY and Shen ZJ: MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG. Cancer Lett 353: 201-210, 2014.
38. Li R, Yuan W, Mei W, Yang K and Chen Z: MicroRNA 520d-3p inhibits gastric cancer cell proliferation, migration, and invasion by downregulating EphA2 expression. Mol Cell Biochem 396: 295-305, 2014.
39. Korhan P, Erdal E and Atabey N: MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met. Biochem Biophys Res Commun 450: 1304-1312, 2014.
40. Yang CH, Yue J, Pfeffer SR, Fan M, Paulus E, Hosni-Ahmed A, Sims M, Qayyum S, Davidoff AM, Handorf CR, et al: MicroRNA-21 promotes glioblastoma tumorigenesis by downregulating IGFBP3. J Biol Chem 289: 25079-25087, 2014.
41. Chen X, Wang J, Cheng L and Lu MP: miR-18a downregulates DICER1 and promotes proliferation and metastasis of nasopharyngeal carcinoma. Int J Clin Exp Med 7: 847-855, 2014.
42. Mo X, Zhang F, Liang H, Liu M, Li H and Xia H: miR-544a promotes the invasion of lung cancer cells by targeting cadherina 1 in vitro. Onco Targets Ther 7: 895-900, 2014.
43. Zang W, Wang Y, Du Y, Xuan X, Wang T, Li M, Ma Y, Li P, Chen X, Dong Z, et al: Differential expression profiling of microRNAs and their potential involvement in esophageal squamous cell carcinoma. Tumour Biol 35: 3295-3304, 2014.
44. Cheng W, Gao J, Zhang Z, Ge J, Xu F and Wei Z: Study on microRNAs in urothelial carcinoma (II grade) of the bladder. J Med Postgraduates China 23: 48-52, 2010.
45. Huang Z, Huang S, Wang Q, Liang L, Ni S, Wang L, Sheng W, He X and Du X: MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer Res 71: 2582-2589, 2011.
46. Yao T, Rao Q, Liu L, Zheng C, Xie Q, Liang J and Lin Z: Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in cervical cancer. Virol J 10: 175, 2013.
47. Li WG, Yuan YZ, Qiao MM and Zhang YP: High dose glargine alters the expression profiles of microRNAs in pancreatic cancer cells. World J Gastroenterol 18: 2630-2639, 2012.
48. Xiao Z, Ching Chow S, Han Li C, Chun Tang S, Tsui SK, Lin Z and Chen Y: Role of microRNA-95 in the anticancer activity of Brucein D in hepatocellular carcinoma. Eur J Pharmacol 728: 141-150, 2014.
49. Huang X, Taeb S, Jahangiri S, Emmenegger U, Tran E, Bruce J, Mesci A, Korpela E, Vesprini D, Wong CS, et al: miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res 73: 6972-6986, 2013.
50. Chen X, Chen S, Hang W, Huang H and Ma H: MiR-95 induces proliferation and chemo- or radioresistance through directly targeting sorting nexin1 (SNX1) in non-small cell lung cancer. Biomed Pharmacother 68: 589-595, 2014.
51. Skalsky RL and Cullen BR: Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS One 6: e24248, 2011.
52. Wan J, Zhou J, Zhao H, Wang M, Wei Z, Gao H, Wang Y and Cui H: Sonic hedgehog pathway contributes to gastric cancer cell growth and proliferation. Biores Open Access 3: 53-59, 2014.
53. Huang L, Walter V, Hayes DN and Onaitis M: Hedgehog-GLI signaling inhibition suppresses tumor growth in squamous lung cancer. Clin Cancer Res 20: 1566-1575, 2014.
54. An Y, Cai B, Chen J, Lv N, Yao J, Xue X, Tu M, Tang D, Wei J, Jiang K, et al: MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. Cancer Lett 329: 228-235, 2013.
55. Luongo C, Ambrosio R, Salzano S, Dlugosz AA, Missero C and Dentice M: The sonic hedgehog-induced type 3 deiodinase facilitates tumorigenesis of basal cell carcinoma by reducing Gli2 inactivation. Endocrinology 155: 2077-2088, 2014.
56. Perrot CY, Gilbert C, Marsaud V, Postigo A, Javelaud D and Mauviel A: GLI2 cooperates with ZEB1 for transcriptional repression of CDH1 expression in human melanoma cells. Pigment Cell Melanoma Res 26: 861-873, 2013.
57. Lattanzio R, Marchisio M, La Sorda R, Tinari N, Falasca M, Alberti S, Miscia S, Ercolani C, Di Benedetto A, Perracchio L, et al CINBO (Consorzio Interuniversitario Nazionale per Bio-Oncologia): Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy. Int J Cancer 132: 1022-1031, 2013.
58. Ma LW, Zhou ZT, He QB and Jiang WW: Phospholipase C-γ1 expression correlated with cancer progression of potentially malignant oral lesions. J Oral Pathol Med 42: 47-52, 2013.
59. Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, Wedge DC, Ramakrishna M, Cooke SL, Pillay N, et al: Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet 46: 376-379, 2014.
60. Vaqué JP, Gómez-López G, Monsálvez V, Varela I, Martínez N, Pérez C, Domínguez O, Graña O, Rodríguez-Peralto JL, Rodríguez-Pinilla SM, et al: PLCG1 mutations in cutaneous T-cell lymphomas. Blood 123: 2034-2043, 2014.
61. Meyer RD, Husain D and Rahimi N: c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLCγ1. Oncogene 30: 2198-2206, 2011.
62. Phillips-Mason PJ, Kaur H, Burden-Gulley SM, Craig SE and Brady-Kalnay SM: Identification of phospholipase C gamma1 as a protein tyrosine phosphatase mu substrate that regulates cell migration. J Cell Biochem 112: 39-48, 2011.
63. Yang J, Song X, Chen Y, Lu XA, Fu Y and Luo Y: PLCγ1-PKCγ signaling-mediated Hsp90α plasma membrane translocation facilitates tumor metastasis. Traffic 15: 861-878, 2014.
64. 2+-, and reactive oxygen species-dependent pathway in HepG2 human hepatocellular carcinoma cells. Apoptosis 19: 682-697, 2014.
65. Kortum RL, Rouquette-Jazdanian AK, Miyaji M, Merrill RK, Markegard E, Pinski JM, Wesselink A, Nath NN, Alexander CP, Li W, et al: A phospholipase C-γ1-independent, RasGRP1-ERK-dependent pathway drives lymphoproliferative disease in linker for activation of T cells-Y136F mutant mice. J Immunol 190: 147-158, 2013.
66. Zhang Q, Yu C, Peng S, Xu H, Wright E, Zhang X, Huo X, Cheng E, Pham TH, Asanuma K, et al: Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway. Gastroenterology 146: 461-472.e6, 2014.
67. Yang JM, Vassil AD and Hait WN: Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol 60: 674-680, 2001.